Fluorescent probes for mapping tumorigenic parameters, polarity and viscosity: implications for future chemotherapeutics
Chemical Communications · 2026
DOI: 10.1039/d6cc06147h ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Chemical Communications, 2026. Verfasst von Shayeri Biswas und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Chung-Ang University, Seoul, 06974, Republic of Korea. minheelee@cau.ac.kr. Die Arbeit nennt 105 Literaturangaben. Gefördert von: National Research Foundation of Korea, Science and Engineering Research Board.
Abstract (Originalsprache)
Fluorescent probes for mapping intracellular polarity, viscosity, and LDs in cancer cells, and the emerging potential of LD-targeted therapeutic approaches for future cancer diagnosis and treatment.
Autor:innen und Institutionen
- Department of Chemistry, Chung-Ang University, Seoul, 06974, Republic of Korea. minheelee@cau.ac.kr.
- Centre for Interdisciplinary Sciences, JIS Institute of Advanced Studies and Research (JISIASR), JIS University, JIS School of Medical Science and Research Campus, 51, South Nayabaz, GIP Colony, Santragachi, Howrah, 711…
Förderung
- National Research Foundation of Korea
- Science and Engineering Research Board
Zitieren
APA
Biswas, S., Choi, W. S., Bhuniya, S., & Lee, M. H. (2026). Fluorescent probes for mapping tumorigenic parameters, polarity and viscosity: implications for future chemotherapeutics. Chemical Communications. https://doi.org/10.1039/d6cc06147h
Vancouver
Biswas S, Choi WS, Bhuniya S, Lee MH. Fluorescent probes for mapping tumorigenic parameters, polarity and viscosity: implications for future chemotherapeutics. Chemical Communications. 2026. doi:10.1039/d6cc06147h
BibTeX
@article{Biswas2026,
author = {Biswas, Shayeri and Choi, Woo Seok and Bhuniya, Sankarprasad and Lee, Min Hee},
title = {Fluorescent probes for mapping tumorigenic parameters, polarity and viscosity: implications for future chemotherapeutics},
journal = {Chemical Communications},
year = {2026},
doi = {10.1039/d6cc06147h}
}
EUVIMED